Alphyn Biologics

Executive Summary

Alphyn Biologics is a clinical-stage dermatology company focused on developing first-in-class, steroid-free topical therapies for severe skin diseases. Its proprietary Zabalafin Platform generates Multi-Target Therapeutics (MTTs) that simultaneously address multiple symptoms and underlying causes of skin conditions. The lead candidate, zabalafin hydrogel (AB-101a), is being evaluated in a Phase 2b trial for atopic dermatitis and has completed enrollment in a Phase 2 trial for molluscum contagiosum. The company's approach aims to provide effective alternatives to corticosteroids, potentially reducing side effects and broadening treatment options for patients with chronic inflammatory and infectious skin disorders. Alphyn is privately held, headquartered in Boston, and was founded in 2016.

Upcoming Catalysts (preview)

• Q1 2027Phase 2b Atopic Dermatitis Topline Data60% success
• Q4 2026Phase 2 Molluscum Contagiosum Topline Data70% success
• TBDPotential Licensing or Partnership Deal50% success